MX2017005156A - Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida. - Google Patents

Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida.

Info

Publication number
MX2017005156A
MX2017005156A MX2017005156A MX2017005156A MX2017005156A MX 2017005156 A MX2017005156 A MX 2017005156A MX 2017005156 A MX2017005156 A MX 2017005156A MX 2017005156 A MX2017005156 A MX 2017005156A MX 2017005156 A MX2017005156 A MX 2017005156A
Authority
MX
Mexico
Prior art keywords
drug antibody
determination
effector function
humanized
drug
Prior art date
Application number
MX2017005156A
Other languages
English (en)
Inventor
Stubenrauch Kay-Gunnar
Wessels Uwe
Umaña Pablo
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017005156A publication Critical patent/MX2017005156A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con un inmunoensayo de anticuerpo de anti-fármaco para la determinación de la presencia de un anticuerpo anti-fármaco contra un anticuerpo de fármaco humano o humanizado de supresión de la función efectora, en una muestra que comprende la incubación de una muestra que comprende suero de sangre de mamífero con el receptor Fcgamma I humano de longitud completa o un fragmento de unión de región Fc del mismo, de modo que se forma un complejo entre el anticuerpo de anti-fármaco contra el anticuerpo de fármaco humano o humanizado de supresión de la función efectora presente en la muestra y el receptor Fcgamma I humano o el fragmento de unión de la región Fc del mismo, por lo que el receptor Fcgamma I humano de longitud completa o el fragmento de unión de la región Fc del mismo se conjuga a una etiqueta detectable, y la determinación del complejo formado por la etiqueta detectable.
MX2017005156A 2014-11-05 2015-10-22 Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida. MX2017005156A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14191806 2014-11-05
PCT/EP2015/074495 WO2016071119A1 (en) 2014-11-05 2015-10-22 Method for the determination of anti-drug antibodies against an effector function suppressed human or humanized drug antibody

Publications (1)

Publication Number Publication Date
MX2017005156A true MX2017005156A (es) 2017-08-08

Family

ID=52023155

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005156A MX2017005156A (es) 2014-11-05 2015-10-22 Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida.

Country Status (11)

Country Link
US (1) US11340234B2 (es)
EP (2) EP3215853B1 (es)
JP (2) JP6739428B2 (es)
KR (1) KR20170080590A (es)
CN (1) CN107076761B (es)
BR (1) BR112017004810A2 (es)
CA (1) CA2960453A1 (es)
ES (1) ES2991677T3 (es)
MX (1) MX2017005156A (es)
RU (1) RU2719642C2 (es)
WO (1) WO2016071119A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101371140B (zh) * 2006-03-09 2013-11-13 弗·哈夫曼-拉罗切有限公司 抗药物抗体的测定
WO2019235420A1 (ja) * 2018-06-04 2019-12-12 中外製薬株式会社 複合体を検出する方法
IL316308A (en) 2018-07-10 2024-12-01 Regeneron Pharma Modifying binding molecules to minimize pre-existing interactions
KR20250141727A (ko) * 2023-02-07 2025-09-29 에프. 호프만-라 로슈 아게 항-aav 입자 항체 검출 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219730A (en) 1982-09-28 1993-06-15 New York University Idiotype-anti-idiotype immunoassay
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
EP0170302A1 (fr) 1984-06-27 1986-02-05 l'Association internationale à but scientifique, dite: Institut international de pathologie cellulaire et moléculaire Procédé de dosage immunologique d'une substance dans un échantillon liquide au moyen d'anticorps anti-idiotypiques
WO1987002778A1 (en) 1985-10-22 1987-05-07 Cooper-Lipotech Solid-phase liposome immunoassay system
NZ255041A (en) 1992-07-13 1996-11-26 Bionebraska Inc Preparation of a recombinant single copy polypeptide or portion thereof modified with a terminal alpha amino carbon reactive group and reactive side chain groups involving biologically added protective groups
US6753189B1 (en) 1998-06-04 2004-06-22 Mizuho Medy Co., Ltd. Detection apparatus and method for the same
EP1917854A1 (en) 2006-11-06 2008-05-07 F. Hoffmann-La Roche Ag Method for producing anti idiotypic antibodies
ES2407603T3 (es) * 2007-12-15 2013-06-13 F. Hoffmann-La Roche Ag Ensayo de distinción
WO2009140242A1 (en) * 2008-05-13 2009-11-19 Genentech, Inc. Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry
BRPI0921718A2 (pt) 2008-11-05 2016-01-05 Teijin Chemicals Ltd composição, método para produzir uma composição, e, artigo moldado
CN105274170A (zh) * 2009-11-05 2016-01-27 弗·哈夫曼-拉罗切有限公司 分泌异源多肽的方法和组合物
EP2354792A1 (en) * 2010-02-08 2011-08-10 Biomonitor A/S Method for detecting anti-drug antibodies
JP2013527444A (ja) * 2010-04-29 2013-06-27 テラディアグ・ソシエテ・アノニム 抗体を検出するための方法
WO2012154253A1 (en) * 2011-02-17 2012-11-15 Prometheus Laboratories Inc. ASSAYS FOR DETECTING AUTOANTIBODIES TO ANTI-TNFα DRUGS
EP2492689B8 (en) * 2011-02-22 2013-12-25 Bernhard-Nocht-Institut für Tropenmedizin Detection of antibodies using an improved immune complex (IC) ELISA
BR112013024574B1 (pt) * 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof

Also Published As

Publication number Publication date
RU2017117273A3 (es) 2019-05-14
EP3215853A1 (en) 2017-09-13
WO2016071119A1 (en) 2016-05-12
EP3736575A1 (en) 2020-11-11
US11340234B2 (en) 2022-05-24
JP2017532570A (ja) 2017-11-02
BR112017004810A2 (pt) 2017-12-12
EP3736575B1 (en) 2024-08-28
KR20170080590A (ko) 2017-07-10
CN107076761B (zh) 2020-05-05
RU2719642C2 (ru) 2020-04-21
ES2991677T3 (es) 2024-12-04
CN107076761A (zh) 2017-08-18
US20170343560A1 (en) 2017-11-30
JP2020170001A (ja) 2020-10-15
CA2960453A1 (en) 2016-05-12
JP6739428B2 (ja) 2020-08-12
EP3736575C0 (en) 2024-08-28
EP3215853B1 (en) 2022-11-16
RU2017117273A (ru) 2018-12-06

Similar Documents

Publication Publication Date Title
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
MX2015012823A (es) Ensayo de combinacion de antigeno-anticuerpo del virus de la hepatitis c (vhc) y metodos y composiciones para usarlo.
AU2018200278B2 (en) Antibodies to aripiprazole and use thereof
EP3933406A3 (en) Antibodies to risperidone and use thereof
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
PE20140612A1 (es) Estratificaciones a base de bcma y terapia para pacientes con mieloma multiple
EA202190237A1 (ru) Способы уменьшения мешающего влияния мишени лекарственного средства в иммунологическом анализе на антитела к лекарственному средству (ada)
MX365787B (es) Anticuerpos modificados de unión a receptor de fc neonatal (fcrn) humano y uso de los mismos.
BR112015022844A2 (pt) métodos para detecção de anticorpos para doadores específicos e sistemas para pratica destes
WO2014031668A3 (en) Antibodies to quetiapine and use thereof
AR098126A1 (es) Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos
WO2014031662A3 (en) Antibodies to olanzapine and use thereof
BR112022005404A2 (pt) Anticorpo monoclonal contra a proteína de ativação de fibroblastos canina que reage de forma cruzada com a proteína de ativação de fibroblastos de camundongo e humana (fap)
MX2017005156A (es) Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida.
RU2015104737A (ru) Способ обнаружения мультиспецифического связывающего агента
BR112018017336A2 (pt) método in vitro para detectar um anticorpo para p53 (anticorpo anti-p53) em uma amostra e polipeptídeo de fusão
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
EP3467498A4 (en) MONOCLONAL ANTI-HUMAN HEMOGLOBIN ANTIBODY OR ANTIBODY KIT, INSOLUBLE CARRIER PARTICLE TO WHICH THE MONOCLONAL ANTI-HUMAN HEMOGLOBIN ANTIBODY IS IMMOBILIZED, AND MEASURING REAGENT AND MEASURING METHODS USED THEREOF
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
PH12019500687A1 (en) Point of care assays
BR112015018834A2 (pt) método para a detecção de um anticorpo do rato, utilização de uma mistura de anticorpos monoclonais e utilização de um anticorpo
ZA202102545B (en) Plant produced avian influenza antigens and their uses in diagnostic assays and devices
SG10201809158TA (en) Device and method for detecting blood group antigens by means of an incomplete antibody
RU2012127077A (ru) Методика проведения иммунохроматографического анализа для серодиагностики
RU2012154230A (ru) Способ количественного определения d-антигена полиовирусов 1-3 типов